Importantly, insulin treatment (Glargine Lantus; 0.2 U/kg/day, once-daily subcutaneous injection) was able to extend the lifespan of Kcnk16 L114P (P/P) neonates, suggesting lethality results from hyperglycemia due to inadequate insulin secretion (Figure 1O). This evidence concerns the gene KCNK16 and Hyperglycemia.